ArticleDrugs - real world outcomes2026
Use of Sotatercept in France since Its Availability in June 2024: A Nationwide Study from the French Health Data System (SNDS).
Article in Drugs - real world outcomes, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPulmonary arterial hypertension (PAH) is a rare, severe and progressive disease associated with poor quality of life and high mortality. Sotatercept, a first-in-class fusion protein, has recently been shown to provide substantial clinical benefit as add-on therapy in PAH and was made available in France in 2024 through an early access program, with eligibility criteria that progressively broadened over time.
objectivesWe aimed to describe the characteristics of the first patients treated with sotatercept in France, its real-world administration patterns, and associated changes in background PAH therapy.
methodsUsing the French National Early Access and Expensive Drugs Cohort (AP-MO), derived from the French Health Data System (SNDS), we included all patients who initiated sotatercept since the start of the early access program and followed them until 31 October 2025. Baseline characteristics included sex, age, social deprivation index, comorbidities, and time since treatment initiation. Changes in background PAH therapy were also described.
resultsWe identified 257 patients treated with sotatercept (median age 53 years; 75.5% women; median follow-up 8.9 months). Among patients with ≥ 90 days follow-up (n = 205), background therapy remained unchanged in 67% of patients. Most administrations followed the expected 21-day interval, and 94.2% received at least one dose renewal. Thirteen deaths occurred during follow-up (0.55 per 100 person-months), and two patients underwent lung transplantation.
conclusionsThese findings provide the first real-world, nationwide insights into sotatercept use in routine clinical practice, showing treatment patterns broadly consistent with initial recommendations, including maintenance of background therapy and adherence to the recommended dosing interval. Further studies are warranted to assess the long-term effectiveness and safety of sotatercept.
Identifiers
42734777What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.